WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

A10BA Biguanides
A10BB Sulfonylureas

The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.

The DDD for gliclazide is based on the modified release formulation.

A10BC Sulfonamides (heterocyclic)
A10BD Combinations of oral blood glucose lowering drugs

Combinations with thioctic acid are allowed in A10BD05.

It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components. One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily. The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.

See list of DDDs for combined products, www.whocc.no

A10BF Alpha glucosidase inhibitors
A10BG Thiazolidinediones

The DDD for troglitazone is based on combination therapy. The DDDs for rosiglitazone and pioglitazone are based on monotherapy.

A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BX Other blood glucose lowering drugs, excl. insulins

Low strength tablets (e.g. 0.8 mg) of bromocriptine are classified in G02CB01.

Nateglinide in combination with thioctic acid is classified in A10BX03.

Last updated: 2017-12-20